Patents by Inventor Jonathan R. Brody

Jonathan R. Brody has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220409611
    Abstract: Described herein are compositions of pyrvinium salts suitable for oral administration. These compositions are in the form of solutions and demonstrate bioavailability both in blood plasma and in pancreatic tissue. Also described herein are methods of treating, ameliorating, and/or preventing pancreatic cancer, including orally administering a composition comprising pyrvinium pamoate.
    Type: Application
    Filed: October 21, 2020
    Publication date: December 29, 2022
    Inventors: Jonathan R. Brody, Christopher William Schultz
  • Publication number: 20220211657
    Abstract: Aspects of the technology described herein are directed to a method of treating gastrointestinal cancer in a subject. This method involves selecting a subject, where the subject (i) has been diagnosed with a gastrointestinal cancer and (ii) has (a) a pathogenic mutation in one or more homologous recombination-DNA damage repair (HR-DDR) pathway genes and/or (b) a family history suggestive of a breast or ovarian cancer syndrome; and administering to the subject an effective amount of a Poly(ADP ribose) polymerase (PARP) inhibitor, in combination with oxaliplatin and an antimetabolite. Methods of treating a gastrointestinal tumor in a subject and of increasing sensitivity of gastrointestinal tumor cells to oxaliplatin are also disclosed.
    Type: Application
    Filed: May 13, 2020
    Publication date: July 7, 2022
    Inventors: Michael J. PISHVAIAN, Jonathan R. BRODY, John L. MARSHALL
  • Publication number: 20120149647
    Abstract: Disclosed are compositions and methods relating to the treatment of a disease with a nucleoside analog, such as gemcitabine or Ara-C, and a polynucleotide construct encoding for an mRNA binding protein, such as Human antigen R.
    Type: Application
    Filed: March 17, 2010
    Publication date: June 14, 2012
    Inventors: Jonathan R. Brody, Agnieszka K. Witkiewicz
  • Patent number: 7811437
    Abstract: A series of low molarity conductive media based on non-buffering univalent cations, such as sodium chloride-sodium acetate (SCA), sodium boric acid (SB), lithium boric acid, and lithium acetate mitigate the “runaway” positive feedback heating loop produced by conventional media containing biological amine buffers and permit improved DNA electrophoresis under the conditions of low salt concentration. These media serve well in ultra-fast DNA electrophoresis and in high-resolution separations of RNA and DNA fragments.
    Type: Grant
    Filed: October 6, 2006
    Date of Patent: October 12, 2010
    Assignee: Faster Better Media LLC
    Inventors: Scott E. Kern, Jonathan R. Brody
  • Patent number: 7163610
    Abstract: A series of low molarity conductive media based on non-buffering univalent cations, such as sodium chloride-sodium acetate (SCA), sodium boric acid (SB), lithium boric acid, and lithium acetate mitigate the “runaway” positive feedback heating loop produced by conventional media containing biological amine buffers and permit improved DNA electrophoresis under the conditions of low salt concentration. These media serve well in ultra-fast DNA electrophoresis and in high-resolution separations of RNA and DNA fragments.
    Type: Grant
    Filed: November 4, 2004
    Date of Patent: January 16, 2007
    Assignee: Faster Better Media LLC
    Inventors: Scott E. Kern, Jonathan R. Brody
  • Patent number: 6930175
    Abstract: pp32 is a member of a highly conserved family of differentiation-regulated nuclear proteins that is highly expressed in nearly all human prostatic adenocarcinomas of Gleason Grade?5. This contrasts with the low percentage of prostate tumors that express molecular alterations in proto-oncogens or demonstrate tumor suppressor mutation or loss of heterozygosity. By analysis of specimens of human prostatic adenocarcinoma and paired adjacent normal prostate from three individual patients, the inventors have shown that normal prostate continues to express normal pp32, whereas three of three sets of RT-PCR-amplified transcripts from prostatic adenocarcinomas display multiple cancer-associated coding sequence changes. The cancer-associated sequence changes appear to be functionally significant. Normal pp32 exerts antineoplastic effects through suppression of transformation. In contrast, cancer-associated pp32 variants augment, rather than inhibit, transformation.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: August 16, 2005
    Assignee: The Johns Hopkins University School of Medicine
    Inventors: Gary R. Pasternack, Gerald J. Kocheavar, Jonathan R. Brody, Shrihari S. Kadkol
  • Publication number: 20030129631
    Abstract: pp32 is a member of a highly conserved family of differentiation-regulated nuclear proteins that is highly expressed in nearly all human prostatic adenocarcinomas of Gleason Grade ≧5. This contrasts with the low percentage of prostate tumors that express molecular alterations in proto-oncogens or demonstrate tumor suppressor mutation or loss of heterozygosity. By analysis of specimens of human prostatic adenocarcinoma and paired adjacent normal prostate from three individual patients, the inventors have shown that normal prostate continues to express normal pp32, whereas three of three sets of RT-PCR-amplified transcripts from prostatic adenocarcinomas display multiple cancer-associated coding sequence changes. The cancer-associated sequence changes appear to be functionally significant. Normal pp32 exerts antineoplastic effects through suppression of transformation. In contrast, cancer-associated pp32 variants augment, rather than inhibit, transformation.
    Type: Application
    Filed: October 18, 2002
    Publication date: July 10, 2003
    Inventors: Gary R. Pasternack, Gerald J. Kocheavar, Jonathan R. Brody, Shrihari S. Kadkol